Skip to content
HowShorted

REVIVA PHARMACEUTICALS HOLDINGS, INC. short interest in 2020

In 2020, REVIVA PHARMACEUTICALS HOLDINGS, INC.'s disclosed short interest ran from 1.82% of shares outstanding on 15 Jan 2020 to 2.94% on 13 Nov 2020, a change of +1.12 percentage points. The year's high was 2.94% on 15 Jul 2020 and its low 1.81% on 14 Feb 2020, averaging 2.33% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 999.99 days on 15 Oct 2020. Full history: REVIVA PHARMACEUTICALS HOLDINGS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for REVIVA PHARMACEUTICALS HOLDINGS, INC. in 2020

2020 in figures

Start of year
1.82% (15 Jan 2020)
End of year
2.94% (13 Nov 2020)
Change
+1.12 pp
High
2.94% (15 Jul 2020)
Low
1.81% (14 Feb 2020)
Average
2.33%
Highest days to cover
999.99 (15 Oct 2020)
SEC filings marked
4

Every report in 2020

REVIVA PHARMACEUTICALS HOLDINGS, INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20201.82%882.4810-Q filed
31 Jan 20201.82%210.71
14 Feb 20201.81%4.43
28 Feb 20201.81%21.23
13 Mar 20201.81%3.27
31 Mar 20201.84%2.16
15 Apr 20201.86%20.60
30 Apr 20201.86%18.87
15 May 20201.96%4.9810-K filed
29 May 20201.96%6.13
15 Jun 20201.98%242.13
30 Jun 20201.97%26.42
15 Jul 20202.94%19.8310-Q filed
31 Jul 20202.93%4.83
14 Aug 20202.92%39.30
31 Aug 20202.92%6.95
15 Sep 20202.92%7.16
30 Sep 20202.92%22.34
15 Oct 20202.93%999.9910-Q filed
30 Oct 20202.93%18.82
13 Nov 20202.94%4.16

See also: REVIVA PHARMACEUTICALS HOLDINGS, INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.